{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:05:33Z","timestamp":1793106333996,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Nature Scientific Research Fund of China","award":["81001052"],"award-info":[{"award-number":["81001052"]}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"crossref","award":["2011B031800222"],"award-info":[{"award-number":["2011B031800222"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.clml.2011.12.002","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T13:12:31Z","timestamp":1328015551000},"page":"106-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival"],"prefix":"10.1016","volume":"12","author":[{"given":"Qingqing","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.12.002_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.critrevonc.2008.10.011","article-title":"Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets","volume":"71","author":"Rodr\u00edguez","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2011.12.002_bib2","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Pripheral T-cell lymphoma unspecified (PTCL-U): a new prognosis model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.002_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdq314","article-title":"Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer\/T-cell lymphoma, nasal type","volume":"22","author":"Huang","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2011.12.002_bib4","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.002_bib5","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.002_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0065-230X(05)94002-5","article-title":"Activation of AKT kinase in cancer: implication for therapeutic targeting","volume":"94","author":"Bellacosa","year":"2005","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.clml.2011.12.002_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2011.12.002_bib8","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/sj.bjc.6600126","article-title":"Activation of AKT\/PKB in breast cancer predicts a worse outcome among endocrine treated patients","volume":"86","author":"Perez-Tenorio","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2011.12.002_bib9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00428-011-1074-1","article-title":"Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial, growth factor, microvascular characteristics and clinical outcome","volume":"458","author":"Saetta","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clml.2011.12.002_bib10","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1182\/blood-2006-04-016907","article-title":"Role of phosphatidylinositol 3'-kinase\/AKT pathway in diffuse large B-cell lymphoma survival","volume":"108","author":"Uddin","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.002_bib11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2141.2010.08123.x","article-title":"High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"149","author":"Hasselblom","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.12.002_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10120-006-0410-7","article-title":"Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy","volume":"10","author":"Murakami","year":"2007","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.clml.2011.12.002_bib13","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1158\/1078-0432.CCR-07-0091","article-title":"Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation","volume":"13","author":"Bedolla","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.12.002_bib14","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/bcr2557","article-title":"Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers","volume":"12","author":"Song","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clml.2011.12.002_bib15","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.002_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0959-437X(98)80062-2","article-title":"Mechanism of activation and function of protein kinase B","volume":"8","author":"Alessi","year":"1998","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.clml.2011.12.002_bib17","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.clml.2011.12.002_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/43474","article-title":"NF\u03baB is a target of AKT in anti-apoptotic PDGF signaling","volume":"401","author":"Romasshkova","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.12.002_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/07357907.2011.584782","article-title":"PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases","volume":"29","author":"Hager","year":"2011","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clml.2011.12.002_bib20","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2011.12.002_bib21","first-page":"5221","article-title":"MMAC1\/PTEN mutations in primary tumor specimens and tumor cell lines","volume":"57","author":"Teng","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.12.002_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/8.2.185","article-title":"PTEN is inversely correlated with the cell survival factor Akt\/PKB and is inactivated via multiple mechanism in haematological malignancies","volume":"8","author":"Dahia","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clml.2011.12.002_bib23","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1158\/0008-5472.CAN-04-0272","article-title":"Phosphorylation of AKT(Ser473) is an excellent predictor of poor clinical outcome in prostate cancer","volume":"64","author":"Kreisberg","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.12.002_bib24","first-page":"3986","article-title":"Akt\/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation","volume":"61","author":"Brognard","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.12.002_bib25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.cdd.4401054","article-title":"Variable apoptotic response of NSCLC cells to inhibition of the MEK\/ERK pathway by small molecules or dominant negative mutants","volume":"9","author":"Brognard","year":"2002","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.clml.2011.12.002_bib26","first-page":"707","article-title":"Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells","volume":"1","author":"Clark","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2011.12.002_bib27","first-page":"780","article-title":"Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance","volume":"63","author":"Clark","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.12.002_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1368-7646(02)00120-6","article-title":"Activation of the PI3K\/Akt pathway and chemotherapeutic resistance","volume":"5","author":"West","year":"2002","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.clml.2011.12.002_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0960-9822(99)80186-9","article-title":"PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2","volume":"9","author":"Balendran","year":"1999","journal-title":"Curr Biol"},{"key":"10.1016\/j.clml.2011.12.002_bib30","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.282.5392.1318","article-title":"Regulation of cell death protease caspase-9 by phosphorylation","volume":"282","author":"Cardone","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.clml.2011.12.002_bib31","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.clml.2011.12.002_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ejps.2006.08.006","article-title":"LY294002, a specific inhibitor of PI3K\/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance","volume":"29","author":"Baranc\u00edk","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.clml.2011.12.002_bib33","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ijc.23122","article-title":"Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K\/Akt pathway","volume":"122","author":"Cordo Russo","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2011.12.002_bib34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.leukres.2008.06.010","article-title":"PI3K\/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines","volume":"33","author":"Garc\u00eda","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2011.12.002_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s13277-010-0131-8","article-title":"Prognostic and predictive values of pERK1\/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy","volume":"32","author":"Shi","year":"2011","journal-title":"Tumour Biol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011006082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011006082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:01Z","timestamp":1761870181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011006082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S2152265011006082"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.12.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}